Current therapy for chronic hepatitis C: The role of direct-acting antivirals.
Current therapy for chronic hepatitis C: The role of direct-acting antivirals.
复制标题
目前慢性丙型肝炎的治疗：直接作用抗病毒药物的作用。
DOI：
10.1016/j.antiviral.2017.02.014
复制
发表时间：
2017-06
影响因子：
7.6
通讯作者：
De Clercq E
中科院分区：
文献类型：
--
作者：
Li G;De Clercq E
抗病毒研究中最令人兴奋的进展之一是发现了直接作用的抗病毒药物(DAA)，可以有效地治疗慢性丙型肝炎病毒(HCV)感染。基于100多项临床试验和现实世界的研究，我们提供了FDA批准的治疗和新发现的抗丙型肝炎病毒药物的全面概述，特别关注药物的有效性、作用机制和安全性。我们发现丙型肝炎病毒药物开发已经在多个方面取得了进展：(I)干扰素方案被无干扰素方案所取代；(Ii)针对不同类型丙型肝炎病毒的药物已演变为适用于所有丙型肝炎病毒的药物；(Iii)基于每天多粒药物的治疗被简化为每天一片；(Iv)持续病毒学应答的药物效力从中等水平(∼60%)提高到高水平(>；90%)；(V)治疗持续时间从48周缩短到12周或8周；以及(Vi)治疗可以口服进行，而不管先前的治疗历史和肝硬变状况如何。然而，尽管在丙型肝炎药物发现方面取得了这些显著的成就，但在难以治疗的患者的管理方面仍然存在挑战。针对丙型肝炎病毒的药物演变为泛基因药物。药物效力从持续病毒学反应的中等水平(∼60%)增加到高水平(>；90%)。疗程从48周缩短到12周或8周。基于每天多片的丙型肝炎病毒治疗被简化为每天一片。无论先前的治疗病史和肝硬变状态如何，丙型肝炎病毒的治疗都是口服的。
One of the most exciting developments in antiviral research has been the discovery of the direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections. Based on more than 100 clinical trials and real-world studies, we provide a comprehensive overview of FDA-approved therapies and newly discovered anti-HCV agents with a special focus on drug efficacy, mechanisms of action, and safety. We show that HCV drug development has advanced in multiple aspects: (i) interferon-based regimens were replaced by interferon-free regimens; (ii) genotype-specific drugs evolved to drugs for all HCV genotypes; (iii) therapies based upon multiple pills per day were simplified to a single pill per day; (iv) drug potency increased from moderate (∼60%) to high (>90%) levels of sustained virologic responses; (v) treatment durations were shortened from 48 to 12 or 8 weeks; and (vi) therapies could be administered orally regardless of prior treatment history and cirrhotic status. However, despite these remarkable achievements made in HCV drug discovery, challenges remain in the management of difficult-to-treat patients. HCV genotype-specific drugs evolve to pan-genotypic drugs. Drug potency increases from moderate (∼60%) to high (>90%) levels of sustained virologic response. Treatment durations are shortened from a 48-week to 12-week or 8-week period. HCV therapies based upon multiple pills per day are simplified to a single pill per day. HCV therapies are administered orally regardless of prior treatment history and cirrhotic status.
登录
查看更多内容
影响因子：
16.6
作者：
Ahmed-Belkacem, Abdelhakim;Colliandre, Lionel;Ahnou, Nazim;Nevers, Quentin;Gelin, Muriel;Bessin, Yannick;Brillet, Rozenn;Cala, Olivier;Douguet, Dominique;Bourguet, William;Krimm, Isabelle;Pawlotsky, Jean-Michel;Guichou, Jean-Francois
通讯作者：
Guichou, Jean-Francois
影响因子：
29.4
作者：
Andreone, Pietro;Colombo, Massimo G.;Bernstein, Barry
通讯作者：
Bernstein, Barry
没有证据表明直接作用抗病毒药物对肝细胞癌复发有影响：来自三个 ANRS 队列的数据
影响因子：
25.7
作者：
通讯作者：
--
影响因子：
29.4
作者：
Boson, Bertrand;Denolly, Solene;Cosset, Francois-Loic
通讯作者：
Cosset, Francois-Loic
DOI：
10.1056/nejmoa1009482
发表时间：
2011-03-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bacon BR;Gordon SC;Lawitz E;Marcellin P;Vierling JM;Zeuzem S;Poordad F;Goodman ZD;Sings HL;Boparai N;Burroughs M;Brass CA;Albrecht JK;Esteban R;HCV RESPOND-2 Investigators
通讯作者：
HCV RESPOND-2 Investigators